Loading...
Loading...
VRTX| Name | Value |
|---|---|
| Revenues | 2,770.2M |
| Cost of Revenue | 363.0M |
| Gross Profit | 2,407.2M |
| Operating Expense | 1,777.1M |
| Operating I/L | 630.1M |
| Other Income/Expense | 100.3M |
| Interest Income | 120.9M |
| Pretax | 730.4M |
| Income Tax Expense | 84.1M |
| Net Income/Loss | 646.3M |
Vertex Pharmaceuticals Incorporated is a biotechnology company specializing in developing and commercializing therapies for cystic fibrosis. The company's revenue is generated through the sale of its products, including SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, which are targeted at treating specific mutations in the cystic fibrosis transmembrane conductance regulator gene. Additionally, Vertex has a pipeline of potential treatments in various stages of clinical trials, such as VX-864 for AAT deficiency, VX-147 for kidney diseases, VX-880 for Type 1 Diabetes, VX-548 for pain treatments, and CTX001 for severe SCD and TDT. Vertex sells its products primarily through specialty pharmacies, distributors, and retail chains in the United States and internationally.
